Alpha-1-antitrypsin gene therapy-inhalation - Aradigm/geneRx+Alternative Names: Alphagen
Latest Information Update: 19 Apr 2007
At a glance
- Originator Aradigm Corporation; geneRx+
- Developer Aradigm Corporation
- Class Gene therapies
- Mechanism of Action Trypsin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Emphysema
Most Recent Events
- 26 Sep 2002 Preclinical trials in emphysema in USA (Inhalation)